# Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

> **NCT02997982** · PHASE2 · COMPLETED · sponsor: **Hugo Lovheim** · enrollment: 33 (actual)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment
- Herpes Simplex

## Interventions

- **DRUG:** Valaciclovir 500Mg Tablet

## Key facts

- **NCT ID:** NCT02997982
- **Lead sponsor:** Hugo Lovheim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2020-03-04
- **Final completion:** 2020-03-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997982, "Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02997982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*